Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 627

1.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Jan 21. doi: 10.1038/s41391-018-0124-z. [Epub ahead of print]

PMID:
30664734
2.

Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.

Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM.

Eur Urol. 2019 Jan 9. pii: S0302-2838(18)31048-0. doi: 10.1016/j.eururo.2018.12.040. [Epub ahead of print]

PMID:
30638635
3.

Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.

Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M 3rd, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA.

Urology. 2018 Dec 21. pii: S0090-4295(18)31321-9. doi: 10.1016/j.urology.2018.09.038. [Epub ahead of print]

PMID:
30580002
4.

Meta-analysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR.

J Nucl Med. 2018 Dec 7. pii: jnumed.118.219501. doi: 10.2967/jnumed.118.219501. [Epub ahead of print]

PMID:
30530831
5.

First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer.

Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y.

J Nucl Med. 2018 Nov 21. pii: jnumed.118.220715. doi: 10.2967/jnumed.118.220715. [Epub ahead of print]

PMID:
30464040
6.

Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial.

Winters-Stone KM, Kenfield SA, Van Blarigan EL, Moe EL, Ramsdill JW, Daniel K, Macaire G, Paich K, Kessler ER, Kucuk O, Gillespie TW, Lyons KS, Beer TM, Broering JM, Carroll PR, Chan JM.

JMIR Res Protoc. 2018 Nov 15;7(11):e11257. doi: 10.2196/11257.

7.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2018 Oct 13. doi: 10.1093/jnci/djy141. [Epub ahead of print]

PMID:
30321406
8.

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA.

Radiology. 2018 Dec;289(3):730-737. doi: 10.1148/radiol.2018180788. Epub 2018 Sep 18.

PMID:
30226456
9.

Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.

Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR.

Eur Urol. 2018 Nov;74(5):668-675. doi: 10.1016/j.eururo.2018.08.020. Epub 2018 Sep 1.

PMID:
30181067
10.

Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.

Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR.

J Urol. 2019 Feb;201(2):300-307. doi: 10.1016/j.juro.2018.08.047.

PMID:
30179620
11.

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):117-124. doi: 10.1038/s41391-018-0084-3. Epub 2018 Aug 31.

PMID:
30171230
12.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
13.

Effect of Oscillation on Perineal Pressure in Cyclists: Implications for Micro-Trauma.

Sanford T, Gadzinski AJ, Gaither T, Osterberg EC, Murphy GP, Carroll PR, Breyer BN.

Sex Med. 2018 Sep;6(3):239-247. doi: 10.1016/j.esxm.2018.05.002. Epub 2018 Jun 20.

14.

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.

Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR.

Eur Urol. 2018 Oct;74(4):444-452. doi: 10.1016/j.eururo.2018.05.014. Epub 2018 May 28.

PMID:
29853306
15.

USPTF Prostate Cancer Screening Recommendations-A Step in the Right Direction.

Carroll PR.

JAMA Surg. 2018 Aug 1;153(8):701-702. doi: 10.1001/jamasurg.2018.1283. No abstract available.

PMID:
29801146
16.

Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?

Spratt DE, Carroll PR.

J Clin Oncol. 2018 Oct 10;36(29):2914-2917. doi: 10.1200/JCO.2018.78.6236. Epub 2018 May 21. No abstract available.

PMID:
29782208
17.

Development of a stress response therapy targeting aggressive prostate cancer.

Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D.

Sci Transl Med. 2018 May 2;10(439). pii: eaar2036. doi: 10.1126/scitranslmed.aar2036.

18.

Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.

Sahoo D, Wei W, Auman H, Hurtado-Coll A, Carroll PR, Fazli L, Gleave ME, Lin DW, Nelson PS, Simko J, Thompson IM, Leach RJ, Troyer DA, True LD, McKenney JK, Feng Z, Brooks JD.

Oncotarget. 2018 Jan 5;9(5):6550-6561. doi: 10.18632/oncotarget.23973. eCollection 2018 Jan 19.

19.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

PMID:
29433975
20.

Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW.

Eur Urol. 2018 May;73(5):706-712. doi: 10.1016/j.eururo.2018.01.016. Epub 2018 Feb 9.

PMID:
29433973
21.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

PMID:
29185869
22.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

23.

Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™).

Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll PR, Van Blarigan EL, Chan JM.

Prostate. 2018 Jan;78(1):32-39. doi: 10.1002/pros.23441. Epub 2017 Nov 6.

24.

Impact of the integration of proton magnetic resonance imaging spectroscopy to PI-RADS 2 for prediction of high grade and high stage prostate cancer.

Leapman MS, Wang ZJ, Behr SC, Kurhanewicz J, Zagoria RJ, Carroll PR, Westphalen AC.

Radiol Bras. 2017 Sep-Oct;50(5):299-307. doi: 10.1590/0100-3984.2016.0117.

25.

Cycling, and Male Sexual and Urinary Function: Results from a Large, Multinational, Cross-Sectional Study.

Awad MA, Gaither TW, Murphy GP, Chumnarnsongkhroh T, Metzler I, Sanford T, Sutcliffe S, Eisenberg ML, Carroll PR, Osterberg EC, Breyer BN.

J Urol. 2018 Mar;199(3):798-804. doi: 10.1016/j.juro.2017.10.017. Epub 2017 Oct 13.

PMID:
29031767
26.

Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).

Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR.

PLoS One. 2017 Oct 10;12(10):e0185535. doi: 10.1371/journal.pone.0185535. eCollection 2017.

27.

Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.

Zhou CK, Stanczyk FZ, Hafi M, Veneroso CC, Lynch B, Falk RT, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll PR, Manyak MJ, Sesterhenn IA, Levine PH, Hsing AW, Cook MB.

Prostate. 2017 Dec;77(16):1573-1582. doi: 10.1002/pros.23433. Epub 2017 Oct 2.

28.

Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard.

Starobinets O, Simko JP, Kuchinsky K, Kornak J, Carroll PR, Greene KL, Kurhanewicz J, Noworolski SM.

NMR Biomed. 2017 Dec;30(12). doi: 10.1002/nbm.3796. Epub 2017 Sep 29.

PMID:
28961382
29.

Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.

Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL.

J Urol. 2018 Mar;199(3):719-725. doi: 10.1016/j.juro.2017.09.071. Epub 2017 Sep 20.

PMID:
28941923
30.

Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.

Garcia-Reyes K, Nguyen HG, Zagoria RJ, Shinohara K, Carroll PR, Behr SC, Westphalen AC.

J Urol. 2018 Mar;199(3):699-705. doi: 10.1016/j.juro.2017.09.075. Epub 2017 Sep 20.

PMID:
28941918
31.

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.

Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA.

EJNMMI Res. 2017 Sep 19;7(1):77. doi: 10.1186/s13550-017-0327-7.

32.

The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy.

Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP.

Cancer. 2017 Dec 1;123(23):4574-4582. doi: 10.1002/cncr.30918. Epub 2017 Sep 7.

33.

Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations.

Cook MB, Stanczyk FZ, Wood SN, Pfeiffer RM, Hafi M, Veneroso CC, Lynch B, Falk RT, Zhou CK, Niwa S, Emanuel E, Gao YT, Hemstreet GP, Zolfghari L, Carroll PR, Manyak MJ, Sesterhann IA, Levine PH, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1660-1666. doi: 10.1158/1055-9965.EPI-17-0215. Epub 2017 Aug 22.

34.

Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital.

Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll PR, Breyer BN.

Urol Oncol. 2017 Nov;35(11):663.e9-663.e14. doi: 10.1016/j.urolonc.2017.07.003. Epub 2017 Aug 18.

PMID:
28826701
35.

Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR.

J Nucl Med. 2017 Dec;58(12):1956-1961. doi: 10.2967/jnumed.117.192476. Epub 2017 May 18.

36.

Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy.

Herlemann A, Cowan JE, Carroll PR, Cooperberg MR.

Eur Urol. 2018 Feb;73(2):215-223. doi: 10.1016/j.eururo.2017.04.027. Epub 2017 May 9.

PMID:
28499617
37.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy.

Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY.

JAMA Oncol. 2017 Dec 1;3(12):1663-1672. doi: 10.1001/jamaoncol.2017.0751.

38.

AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.

Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, Pinto PA, Bjurlin MA, Eggener S.

J Urol. 2017 Oct;198(4):832-838. doi: 10.1016/j.juro.2017.04.101. Epub 2017 May 5.

PMID:
28483574
39.

The Fitbit One Physical Activity Tracker in Men With Prostate Cancer: Validation Study.

Van Blarigan EL, Kenfield SA, Tantum L, Cadmus-Bertram LA, Carroll PR, Chan JM.

JMIR Cancer. 2017 Apr 18;3(1):e5. doi: 10.2196/cancer.6935.

40.

Active Surveillance in Younger Men With Prostate Cancer.

Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR.

J Clin Oncol. 2017 Jun 10;35(17):1898-1904. doi: 10.1200/JCO.2016.68.0058. Epub 2017 Mar 27.

41.

Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments.

Vertosick EA, Vickers AJ, Cowan JE, Broering JM, Carroll PR, Cooperberg MR.

J Urol. 2017 Sep;198(3):671-677. doi: 10.1016/j.juro.2017.03.121. Epub 2017 Mar 22.

42.

Low-risk Prostate Cancer: Identification, Management, and Outcomes.

Moschini M, Carroll PR, Eggener SE, Epstein JI, Graefen M, Montironi R, Parker C.

Eur Urol. 2017 Aug;72(2):238-249. doi: 10.1016/j.eururo.2017.03.009. Epub 2017 Mar 18. Review.

PMID:
28318726
43.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

44.

Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?

Masic S, Washington SL 3rd, Carroll PR.

Curr Opin Urol. 2017 May;27(3):231-237. doi: 10.1097/MOU.0000000000000387. Review.

PMID:
28234748
45.

Medicine information exchange networks among healthcare professionals and prescribing in geriatric medicine wards.

Chan B, Reeve E, Matthews S, Carroll PR, Long JC, Held F, Latt M, Naganathan V, Caplan GA, Hilmer SN.

Br J Clin Pharmacol. 2017 Jun;83(6):1185-1196. doi: 10.1111/bcp.13222. Epub 2017 Feb 1.

46.

Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes.

Leapman MS, Cowan JE, Simko J, Roberge G, Stohr BA, Carroll PR, Cooperberg MR.

Eur Urol. 2017 May;71(5):750-759. doi: 10.1016/j.eururo.2016.11.032. Epub 2016 Dec 9.

PMID:
27940155
47.

Tissue Sources for Accurate Measurement of Germline DNA Genotypes in Prostate Cancer Patients Treated With Radical Prostatectomy.

Emami NC, Leong L, Wan E, Van Blarigan EL, Cooperberg MR, Tenggara I, Carroll PR, Chan JM, Witte JS, Simko JP.

Prostate. 2017 Mar;77(4):425-434. doi: 10.1002/pros.23283. Epub 2016 Nov 30.

48.

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators.

Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23.

PMID:
27889277
49.

MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.

Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME, Lin DW, Nelson PS, Thompson IM, True LD, McKenney JK, Feng Z, Fazli L, Brooks JD.

PLoS One. 2016 Nov 15;11(11):e0165236. doi: 10.1371/journal.pone.0165236. eCollection 2016.

50.

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.

Macleod LC, Ellis WJ, Newcomb LF, Zheng Y, Brooks JD, Carroll PR, Gleave ME, Lance RS, Nelson PS, Thompson IM Jr, Wagner AA, Wei JT, Lin DW.

J Urol. 2017 Apr;197(4):1026-1033. doi: 10.1016/j.juro.2016.10.090. Epub 2016 Nov 1.

Supplemental Content

Loading ...
Support Center